Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. It is being developed by CV Therapeutics, Inc.
Investigated for use/treatment in arrhythmia and atrial fibrillation.
CV Therapeutics, Inc., Palo Alto, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.